Gonadotropin-Releasing Hormone Agonists and Bone Density in Congenital Adrenal Hyperplasia: A Call for Further Research

被引：0
|
作者：
Bakhtiani, Priyanka [1 ,2 ]
机构：
[1] Univ Southern Calif, Childrens Hosp Los Angeles, Keck Sch Med, Ctr Endocrinol Diabet & Metab,Dept Pediat, Los Angeles, CA 90026 USA
[2] Univ Southern Calif, Childrens Hosp Los Angeles, Keck Sch Med, Ctr Endocrinol Diabet & Metab,Dept Pediat, 4650 Sunset Blvd, Mail Stop 61, Los Angeles, CA 90026 USA
来源：
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2024年 / 109卷 / 06期
关键词：
congenital adrenal hyperplasia; early puberty; GnRH agonist; bone mineral density; short stature; adrenal; ADULT HEIGHT; ANALOGS;
D O I：
10.1210/clinem/dgad687
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e1458 / e1459
页数：2
相关论文
共 50 条
  • [21] Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration
    Taga, M
    Minaguchi, H
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1996, 75 (02) : 162 - 165
  • [22] Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis
    Senra, J. C.
    Roque, M.
    Talim, M. C. T.
    Reis, F. M.
    Tavares, R. L. C.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2018, 51 (01) : 77 - 86
  • [23] Bone mineral density determinants in adolescents and young adults with congenital adrenal hyperplasia
    Navardauskaite, Ruta
    Vanckaviciene, Aurika
    Verkauskiene, Rasa
    FRONTIERS IN PEDIATRICS, 2024, 12
  • [24] The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention
    Schindler, Adolf E.
    GYNECOLOGICAL ENDOCRINOLOGY, 2009, 25 (12) : 765 - 767
  • [25] A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review
    Jeng, Cherng-Jye
    Chuang, Linus
    Shen, Jenta
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (06) : 767 - 773
  • [26] Ovarian protection with gonadotropin-releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus
    Kado, Ruba
    McCune, W. Joseph
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2020, 64 : 97 - 106
  • [27] Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons
    Dolmans, Marie-Madeleine
    Taylor, Hugh S.
    Rodriguez-Wallberg, Kenny A.
    Blumenfeld, Zeev
    Lambertini, Matteo
    von Wolff, Michael
    Donnez, Jacques
    FERTILITY AND STERILITY, 2020, 114 (04) : 725 - 738
  • [28] The Relationship of Gonadotropin-releasing Hormone Agonists and Anthropometric Indices of Girls with Premature Idiopathic Central Precocious Puberty: A Cohort Study
    Badpeyma, Mohaddeseh
    Molani-Gol, Roghayeh
    Sistanian, Fatemeh
    Khadem-Rezaiyan, Majid
    Eshraghi, Peyman
    Samaei, Fateme
    Faghfouri, Amir Hossein
    Vakili, Rahim
    IRANIAN JOURNAL OF NEONATOLOGY, 2024, 15 (04) : 10 - 16
  • [29] Further evaluation of the biological activity of the unique gonadotropin-releasing hormone peptide in the guinea pig brain
    Gao, Chang-Qing
    Fraeyman, Norbert
    Eertmans, Frank
    Dhooge, Willem
    Kaufman, Jean-Marc
    NEUROSCIENCE LETTERS, 2011, 487 (02) : 246 - 249
  • [30] Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy
    Ripps, BA
    VanGilder, K
    Minhas, B
    Welford, M
    Mamish, Z
    JOURNAL OF REPRODUCTIVE MEDICINE, 2003, 48 (10) : 761 - 766
12345